Evidence map›Paper›PMID 31715145›Full record

ArticleGastroenterology2020

Isoforms of RNF128 Regulate the Stability of Mutant P53 in Barrett's Esophageal Cells.

Dipankar Ray, Paramita Ray, Daysha Ferrer-Torres, Zhuwen Wang, Derek Nancarrow, Hee-Won Yoon, May San Martinho, Tonaye Hinton, Scott Owens, Dafydd Thomas and 6 more

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 24 citations in OpenAlex.

  1. SRSF3 plays a key role in liver cancer sex disparity by facilitating hepatocyte expression of ERα and FOXA.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Dipankar RayDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan. Electronic address: dipray@umich.edu.
Paramita RayDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Daysha Ferrer-TorresDepartment of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.
Zhuwen WangDepartment of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.
Derek NancarrowDepartment of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.
Hee-Won YoonDepartment of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.
May San MartinhoDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Tonaye HintonDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Scott OwensDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Dafydd ThomasDepartment of Pathology, University of Michigan, Ann Arbor, Michigan.
Hui JiangDepartment of Biostatistics, University of Michigan, Ann Arbor, Michigan.
Theodore S LawrenceDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
Jules LinDepartment of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.
Kiran LagisettyDepartment of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.
Andrew C ChangDepartment of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan.
David G BeerDepartment of Radiation Oncology, University of Michigan, Ann Arbor, Michigan; Department of Surgery, Thoracic Surgery, University of Michigan, Ann Arbor, Michigan. Electronic address: dgbeer@umich.edu.
University of Michigan · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
Validation & Pathology CoreU54CA163059 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI RUBENSTEIN, JOEL H, WANG, THOMAS D · 2011 to 2022
$12.1M
RNF128 Regulation of TP53 in Barrett's ProgressionR01CA215596 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BEER, DAVID GEORGE, NANCARROW, DEREK JOHN · 2017 to 2021
$2.1M
Identification of Cell Surface Markers for Risk Stratification of Barrett's Esophagus PatientsF31CA200113 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI FERRER-TORRES, DAYSHA · 2015 to 2016
$68k
NCI NIH HHS F31 CA200113NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA215596NCI NIH HHS U54 CA163059
6 · The paper itself

Abstract

BACKGROUND &

aimsBarrett's esophagus (BE) can progress to dysplasia and esophageal adenocarcinoma (EAC), accompanied by mutations in TP53 that increase the stability of its product, p53. We analyzed BE tissues for messenger RNAs (mRNAs) that associate with BE progression and identified one that affects the stabilization of p53.

methodsWe obtained 54 BE samples collected from patients with high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC), from 1992 through 2015, and performed RNA sequence analyses, including isoform-specific analyses. We performed reverse-transcription polymerase chain reaction analyses of 166 samples and immunohistochemical analyses of tissue microarrays that contained BE tissues from 100 patients with HGD or EAC and normal esophageal squamous mucosa (controls). Proteins were expressed from transfected plasmids or knocked down with small interfering RNAs in BE cells and analyzed by immunoblots and in immunoprecipitation and ubiquitin ligase assays. Athymic nude mice bearing EAC xenograft tumors (grown from OE-33 cells) were given intraperitoneal injections of simvastatin; tumor growth was monitored and tumors were collected and analyzed by immunoblotting for levels of RNF128, p53, and acetylated p53.

resultsProgression of BE to HGD or EAC associated with changes in expression of mRNAs that encoded mucins and promoted inflammation and activation of ATM and the DNA damage response. As tissues progressed from BE to HGD to EAC, they increased expression of mRNAs encoding isoform 1 of RNF128 (Iso1) and decreased expression of Iso2 of RNF128. RNF128 is an E3 ubiquitin ligase that targets p53 for degradation. Incubation of BE cells with interferon gamma caused them to increase expression of Iso1 and reduce expression of Iso2. Iso1 was heavily glycosylated with limited ubiquitin ligase activity for p53, resulting in p53 stabilization. Knockdown of Iso1 in BE and EAC cells led to degradation of the mutant form of p53 and reduced clonogenic survival. In contrast, Iso2 was a potent ligase that reduced levels of the mutant form of p53 in BE cells. In BE cells, Iso2 was hypoglycosylated and degraded, via ATM and GSK3β-mediated phosphorylation and activation of the beta-TrCP1-containing SCF ubiquitin ligase complex. Simvastatin, which degrades the mutant form of p53, also degraded RNF128 Iso1 protein in BE cells and slowed growth of EAC xenograft tumors in mice.

conclusionsWe found that isoform 2 of RNF128 is decreased in BE cells, resulting in increased levels of mutant p53, whereas isoform 1 of RNF128 is increased in BE cells, further promoting the stabilization of mutant p53.

Indexed as

AdenocarcinomaAnimalsBarrett EsophagusCells, CulturedDown-RegulationEsophageal NeoplasmsEsophagusFemaleGene ExpressionGene SilencingGlycosylationHumansHydroxymethylglutaryl-CoA Reductase InhibitorsInterferon-gammaIsoenzymesMiceHydroxymethylglutaryl-CoA Reductase InhibitorsInterferon-gammaIsoenzymesRNA, MessengerRNF128 protein, humanSimvastatinTumor Suppressor Protein p53Ubiquitin-Protein LigasesAlternate IsoformEsophageal CancerPost-Transcriptional RegulationTumor Suppressor

Identifiers

PMID31715145
PMCPMC7429981
OpenAlexW2987150998

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.